Breast Cancer – Current Treatment – Current Treatment: Physician Insights – Breast Cancer (US)

The breast cancer treatment landscape is rapidly evolving. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio) combined with endocrine therapy, are established as first-line treatment options for metastatic HRpositive / HER2-negative disease and have now expanded into the earlystage setting. Biomarker-driven therapies—including Menarini Group’s Orserdu (ESR1-mutant), Novartis’s Piqray and Roche / Chugai Pharmaceutical’s Itovebi (PIK3CA-mutant) and AstraZeneca’s Truqap (PIK3CA / AKT1 / PTEN-mutant)—have expanded treatment options for metastatic HR-positive / HER2-negative disease. Meanwhile, Merck & Co.’s Keytruda has reshaped the treatment paradigm for certain patients with early and metastatic triple-negative breast cancer. PARP inhibitors (AstraZeneca / Merck & Co.’s Lynparza and Pfizer’s Talzenna) offer options for PARP-mutant patients with either triple-negative or HR-positive / HER2-negative disease. Next-generation ADCs (Gilead’s Trodelvy, AstraZeneca / Daiichi Sankyo’s Datroway, and Daiichi Sankyo / AstraZeneca’s Enhertu for HER2low and HER2ultralow disease) have diversified therapy options for metastatic patients. In the HER2-positive metastatic setting, Enhertu´s label expansion into the second line is redefining treatment.

QUESTIONS ANSWERED

• What are the treatment rates for breast cancer by key subtype and line of therapy?
• What are physician-reported testing rates for select biomarkers (e.g., mutations in PIK3CA, ESR1, and PARP, HER2-low / HER2-ultralow status, and PD-L1 expression) in relevant breast cancer subtypes?
• What is the patient share of key drugs and regimens by type of breast cancer?
• What are the main drivers of and key obstacles to the uptake of select therapies?

PRODUCT DESCRIPTION

Through survey data from U.S. physicians, Current Treatment: Physician Insights offers in-depth analyses of the reasons behind treatment dynamics, prescribing behavior, and brand preference, enabling you to:

• Understand the treatment landscape for a disease and how physicians make prescribing decisions.
• Evaluate the drivers and obstacles that influence treatment selection.
• Analyze your brand’s performance from the physician perspective to enhance or defend your competitive position.

Primary research: Survey of 100 medical oncologists in the United States fielded in December 2025.

Key drugs: Ibrance, Kisqali, Verzenio, Lynparza, Talzenna, Piqray, Truqap, Itovebi, Orserdu, Enhertu, Trodelvy, Datroway, Phesgo, Keytruda.